R Ceschin1, B F Kurland2, S R Abberbock3, B M Ellingson4, H Okada5, R I Jakacki6, I F Pollack7, A Panigrahy8. 1. From the Departments of Radiology (R.C., A.P.) Biomedical Informatics (R.C., A.P.), University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania Departments of Radiology (R.C., A.P.). 2. Children's Hospital of Pittsburgh, University of Pittsburgh Cancer Institute (B.F.K., S.R.A., H.O., R.I.J., I.F.P., A.P.) Department of Biostatistics, Graduate School of Public Health (B.F.K.), University of Pittsburgh, Pittsburgh, Pennsylvania. 3. Children's Hospital of Pittsburgh, University of Pittsburgh Cancer Institute (B.F.K., S.R.A., H.O., R.I.J., I.F.P., A.P.). 4. Department of Radiological Sciences (B.M.E.), University of California, Los Angeles, Los Angeles, California. 5. Surgery (H.O.) Neurosurgery (H.O., I.F.P.) Immunology (H.O.) Children's Hospital of Pittsburgh, University of Pittsburgh Cancer Institute (B.F.K., S.R.A., H.O., R.I.J., I.F.P., A.P.). 6. Pediatrics (R.I.J.) Pediatrics (R.I.J.) Children's Hospital of Pittsburgh, University of Pittsburgh Cancer Institute (B.F.K., S.R.A., H.O., R.I.J., I.F.P., A.P.). 7. Neurosurgery (H.O., I.F.P.) Neurosurgery (I.F.P.) Children's Hospital of Pittsburgh, University of Pittsburgh Cancer Institute (B.F.K., S.R.A., H.O., R.I.J., I.F.P., A.P.). 8. From the Departments of Radiology (R.C., A.P.) Biomedical Informatics (R.C., A.P.), University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania Departments of Radiology (R.C., A.P.) Children's Hospital of Pittsburgh, University of Pittsburgh Cancer Institute (B.F.K., S.R.A., H.O., R.I.J., I.F.P., A.P.) panigrahya@upmc.edu.
Abstract
BACKGROUND AND PURPOSE: Immune response to cancer therapy may result in pseudoprogression, which can only be identified retrospectively and may disrupt an effective therapy. This study assesses whether serial parametric response mapping (a voxel-by-voxel method of image analysis also known as functional diffusion mapping) analysis of ADC measurements following peptide-based vaccination may help prospectively distinguish progression from pseudoprogression in pediatric patients with diffuse intrinsic pontine gliomas. MATERIALS AND METHODS: From 2009 to 2012, 21 children, 4-18 years of age, with diffuse intrinsic pontine gliomas were enrolled in a serial peptide-based vaccination protocol following radiation therapy. DWI was acquired before immunotherapy and at 6-week intervals during vaccine treatment. Pseudoprogression was identified retrospectively on the basis of clinical and radiographic findings, excluding DWI. Parametric response mapping was used to analyze 96 scans, comparing ADC measures at multiple time points (from the first vaccine to up to 12 weeks after the vaccine was halted) with prevaccine baseline values. Log-transformed fractional increased ADC, fractional decreased ADC, and parametric response mapping ratio (fractional increased ADC/fractional decreased ADC) were compared between patients with and without pseudoprogression, by using generalized estimating equations with inverse weighting by cluster size. RESULTS: Median survival was 13.1 months from diagnosis (range, 6.4-24.9 months). Four of 21 children (19%) were assessed as experiencing pseudoprogression. Patients with pseudoprogression had higher fitted average log-transformed parametric response mapping ratios (P = .01) and fractional decreased ADCs (P = .0004), compared with patients without pseudoprogression. CONCLUSIONS: Serial parametric response mapping of ADC, performed at multiple time points of therapy, may distinguish pseudoprogression from true progression in patients with diffuse intrinsic pontine gliomas treated with peptide-based vaccination.
BACKGROUND AND PURPOSE: Immune response to cancer therapy may result in pseudoprogression, which can only be identified retrospectively and may disrupt an effective therapy. This study assesses whether serial parametric response mapping (a voxel-by-voxel method of image analysis also known as functional diffusion mapping) analysis of ADC measurements following peptide-based vaccination may help prospectively distinguish progression from pseudoprogression in pediatric patients with diffuse intrinsic pontine gliomas. MATERIALS AND METHODS: From 2009 to 2012, 21 children, 4-18 years of age, with diffuse intrinsic pontine gliomas were enrolled in a serial peptide-based vaccination protocol following radiation therapy. DWI was acquired before immunotherapy and at 6-week intervals during vaccine treatment. Pseudoprogression was identified retrospectively on the basis of clinical and radiographic findings, excluding DWI. Parametric response mapping was used to analyze 96 scans, comparing ADC measures at multiple time points (from the first vaccine to up to 12 weeks after the vaccine was halted) with prevaccine baseline values. Log-transformed fractional increased ADC, fractional decreased ADC, and parametric response mapping ratio (fractional increased ADC/fractional decreased ADC) were compared between patients with and without pseudoprogression, by using generalized estimating equations with inverse weighting by cluster size. RESULTS: Median survival was 13.1 months from diagnosis (range, 6.4-24.9 months). Four of 21 children (19%) were assessed as experiencing pseudoprogression. Patients with pseudoprogression had higher fitted average log-transformed parametric response mapping ratios (P = .01) and fractional decreased ADCs (P = .0004), compared with patients without pseudoprogression. CONCLUSIONS: Serial parametric response mapping of ADC, performed at multiple time points of therapy, may distinguish pseudoprogression from true progression in patients with diffuse intrinsic pontine gliomas treated with peptide-based vaccination.
Authors: T Sugahara; Y Korogi; M Kochi; I Ikushima; Y Shigematu; T Hirai; T Okuda; L Liang; Y Ge; Y Komohara; Y Ushio; M Takahashi Journal: J Magn Reson Imaging Date: 1999-01 Impact factor: 4.813
Authors: L C Hygino da Cruz; I Rodriguez; R C Domingues; E L Gasparetto; A G Sorensen Journal: AJNR Am J Neuroradiol Date: 2011-03-10 Impact factor: 3.825
Authors: Matthew J Wieduwilt; Francisco Valles; Samar Issa; Caroline M Behler; James Hwang; Michael McDermott; Patrick Treseler; Joan O'Brien; Marc A Shuman; Soonmee Cha; Lloyd E Damon; James L Rubenstein Journal: Clin Cancer Res Date: 2012-01-06 Impact factor: 12.531
Authors: Daniel A Hamstra; Thomas L Chenevert; Bradford A Moffat; Timothy D Johnson; Charles R Meyer; Suresh K Mukherji; Douglas J Quint; Stephen S Gebarski; Xiaoying Fan; Christina I Tsien; Theodore S Lawrence; Larry Junck; Alnawaz Rehemtulla; Brian D Ross Journal: Proc Natl Acad Sci U S A Date: 2005-11-02 Impact factor: 11.205
Authors: Krzysztof Gorgolewski; Christopher D Burns; Cindee Madison; Dav Clark; Yaroslav O Halchenko; Michael L Waskom; Satrajit S Ghosh Journal: Front Neuroinform Date: 2011-08-22 Impact factor: 4.081
Authors: Jelena Lazovic; Michael C Jensen; Evette Ferkassian; Brenda Aguilar; Andrew Raubitschek; Russell E Jacobs Journal: Clin Cancer Res Date: 2008-06-15 Impact factor: 12.531
Authors: Mark Jenkinson; Christian F Beckmann; Timothy E J Behrens; Mark W Woolrich; Stephen M Smith Journal: Neuroimage Date: 2011-09-16 Impact factor: 6.556
Authors: Matthew Grech-Sollars; Dawn E Saunders; Kim P Phipps; Ramneek Kaur; Simon M L Paine; Thomas S Jacques; Jonathan D Clayden; Chris A Clark Journal: Neuro Oncol Date: 2013-12-04 Impact factor: 12.300
Authors: P Alcaide-Leon; J Cluceru; J M Lupo; T J Yu; T L Luks; T Tihan; N A Bush; J E Villanueva-Meyer Journal: AJNR Am J Neuroradiol Date: 2020-10-15 Impact factor: 3.825
Authors: Andre D Furtado; Rafael Ceschin; Stefan Blüml; Gary Mason; Regina I Jakacki; Hideho Okada; Ian F Pollack; Ashok Panigrahy Journal: Neuroimaging Clin N Am Date: 2017-02 Impact factor: 2.264
Authors: Rafael Ceschin; Mehmet Kocak; Sridhar Vajapeyam; Ian F Pollack; Arzu Onar-Thomas; Ira J Dunkel; Tina Young Poussaint; Ashok Panigrahy Journal: J Neurooncol Date: 2019-02-27 Impact factor: 4.130
Authors: Paula Alcaide-Leon; Tracy L Luks; Marisa Lafontaine; Janine M Lupo; Hideho Okada; Jennifer L Clarke; Javier E Villanueva-Meyer Journal: J Neurooncol Date: 2019-11-14 Impact factor: 4.130
Authors: Anna J Shangguan; Chong Sun; Bin Wang; Liang Pan; Quanhong Ma; Su Hu; Jia Yang; Aydin Eresen; Yuri Velichko; Vahid Yaghmai; Zhuoli Zhang Journal: Am J Cancer Res Date: 2019-09-01 Impact factor: 6.166
Authors: Eugene I Hwang; Elias J Sayour; Catherine T Flores; Gerald Grant; Robert Wechsler-Reya; Lan B Hoang-Minh; Mark W Kieran; Joanne Salcido; Robert M Prins; John W Figg; Michael Platten; Kate M Candelario; Paul G Hale; Jason E Blatt; Lance S Governale; Hideho Okada; Duane A Mitchell; Ian F Pollack Journal: Nat Cancer Date: 2022-01-20
Authors: Ian F Pollack; Regina I Jakacki; Lisa H Butterfield; Ronald L Hamilton; Ashok Panigrahy; Daniel P Normolle; Angela K Connelly; Sharon Dibridge; Gary Mason; Theresa L Whiteside; Hideho Okada Journal: J Neurooncol Date: 2016-09-13 Impact factor: 4.130
Authors: Fernando Carceller; Lucy A Fowkes; Komel Khabra; Lucas Moreno; Frank Saran; Anna Burford; Alan Mackay; David T W Jones; Volker Hovestadt; Lynley V Marshall; Sucheta Vaidya; Henry Mandeville; Neil Jerome; Leslie R Bridges; Ross Laxton; Safa Al-Sarraj; Stefan M Pfister; Martin O Leach; Andrew D J Pearson; Chris Jones; Dow-Mu Koh; Stergios Zacharoulis Journal: J Neurooncol Date: 2016-05-14 Impact factor: 4.130